-
Something wrong with this record ?
Combinations of a full and partial agonist: Experimental evidence of curved isoboles
M. Ezechiáš
Language English Country Netherlands
Document type Journal Article
- MeSH
- Drug Interactions physiology MeSH
- Drug Partial Agonism * MeSH
- Drug Synergism * MeSH
- Models, Theoretical MeSH
- Dose-Response Relationship, Drug MeSH
- Publication type
- Journal Article MeSH
Concentration addition as a classic null model for toxicology and pharmacology is based on Loewe's mathematical formulation and the linearity of the isoboles. Novel mathematical models, however, propose curved isoboles in certain conditions. This article aims to test the hypothesis of the curvature of isoboles in experimental measurements. With the assumption of linear isoboles, a partial agonist acts as an antagonist above its maximal effect level. The isoboles automatically convert to a positive slope. For curved isoboles, a partial agonist acts as an antagonist at higher effect levels than its maximal effect alone. The discrepancies between effect levels were studied with an estrogen receptor binding assay (BMAEREluc/ERα) using a mixture of 17β-estradiol and fulvestrant as a partial agonist. A mixture of 17β-estradiol and fulvestrant acts as a partial agonist and causes the diminishing of the effect level of 17β-estradiol at a significantly higher level than the maximal effect of their partial-agonistic dose-response curve. Measured, elevated effect levels were well predicted by the mathematical model. Nonlinear isoboles may change our understanding and definition of synergism or antagonism and prompt further attention in receptor theory.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21024891
- 003
- CZ-PrNML
- 005
- 20211026134312.0
- 007
- ta
- 008
- 211013s2021 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.toxlet.2021.06.016 $2 doi
- 035 __
- $a (PubMed)34174339
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Ezechiáš, Martin $u The Laboratory of Environmental Biotechnology, Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, Prague, 142 20, Czech Republic. Electronic address: ezechias@biomed.cas.cz
- 245 10
- $a Combinations of a full and partial agonist: Experimental evidence of curved isoboles / $c M. Ezechiáš
- 520 9_
- $a Concentration addition as a classic null model for toxicology and pharmacology is based on Loewe's mathematical formulation and the linearity of the isoboles. Novel mathematical models, however, propose curved isoboles in certain conditions. This article aims to test the hypothesis of the curvature of isoboles in experimental measurements. With the assumption of linear isoboles, a partial agonist acts as an antagonist above its maximal effect level. The isoboles automatically convert to a positive slope. For curved isoboles, a partial agonist acts as an antagonist at higher effect levels than its maximal effect alone. The discrepancies between effect levels were studied with an estrogen receptor binding assay (BMAEREluc/ERα) using a mixture of 17β-estradiol and fulvestrant as a partial agonist. A mixture of 17β-estradiol and fulvestrant acts as a partial agonist and causes the diminishing of the effect level of 17β-estradiol at a significantly higher level than the maximal effect of their partial-agonistic dose-response curve. Measured, elevated effect levels were well predicted by the mathematical model. Nonlinear isoboles may change our understanding and definition of synergism or antagonism and prompt further attention in receptor theory.
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a lékové interakce $x fyziologie $7 D004347
- 650 12
- $a parciální agonismus léků $7 D054333
- 650 12
- $a synergismus léků $7 D004357
- 650 _2
- $a teoretické modely $7 D008962
- 655 _2
- $a časopisecké články $7 D016428
- 773 0_
- $w MED00004537 $t Toxicology letters $x 1879-3169 $g Roč. 350, č. - (2021), s. 22-29
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34174339 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026134318 $b ABA008
- 999 __
- $a ok $b bmc $g 1714094 $s 1145398
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 350 $c - $d 22-29 $e 20210624 $i 1879-3169 $m Toxicology letters $n Toxicol Lett $x MED00004537
- LZP __
- $a Pubmed-20211013